Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients

Correction to: Cancer Immunology, Immunotherapy 10.1007/s00262-023-03436-0

The original version of this article unfortunately contained a mistake. In the Table 1, some of the endocrine tests every 3–6 months are misplaced under the column "every 4–6 weeks".

Table 1.

Essential laboratory and functional tests to evaluate before and during treatment with immune checkpoint inhibitors (ICIs)

	Prior to ICI treatment	During ICI treatment
	Baseline	During the first 3 months		After the first 3 months
		Every ICI administration	Every 4–6 weeks	Every 4–6 weeks	Every 3–6 months
Liver	AST, ALT, GGT, ALP, total bilirubin	AST, ALT, GGT, ALP, total bilirubin	–	AST, ALT, GGT, ALP, total bilirubin	–
Endocrine function	Cortisol, TSH, fT3, fT4, AMH a, FSH, LH, Estradiol b, Glucose, Hb1Ac	TSH, fT4, fT3	–	–	TSH, fT4, fT3, AMH, FSH, LH, Estradiol, Hb1Ac
Heart	ECG, CK, Troponin T and I Echocardiographyc	CK, Troponin T and Id	–	CK, Troponin Td	–
Kidney	Creatinine, Urea, Urine dipstick	Creatinine, Urea	–	Creatinine, Urea	Urine dipstick
Fluid and electrolyte balance	Sodium, Potassium	Sodium, Potassium	–	Sodium, Potassium	–
Bone metabolism	Calcium, Albumin, Vitamin D3	–	–	–	Calcium, Albumin
Bone marrow	Complete blood count	–	Complete blood count	Complete blood count	–
Latent infections	Hepatitis B and C, HIV, Tuberculosis	–	–	–	–
Coagulation and fibrinolysis	INR, PT, PTT, D-Dimer, Fibrinogen, Ferritin	–	–	–	INR, PT, PTT
Gastrointestinal function	FC, C.diff, CMVe	–	–	–	–
Lung function	Spirometry and DLCOf	–	–	–	–
Neurological function	Neurological examination (cranial nerves and motoric and sensory function)	–	–	–	–

ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, DLCO diffusing capacity for carbon monoxide, ECG electrocardiogram, FC fecal calprotectin, FSH follicle-stimulating hormone, GGT gamma-glutamyl transpeptidase, INR international normalized ratio, LDH lactate dehydrogenase, LH luteinizing hormone, PT prothrombin time, PTT partial thromboplastin time, TSH thyroid-stimulating hormone

^aFemale patients 18–42 years old

^bPremenopausal female patients

^cPatients at risk of developing ICI-related myocarditis (e.g., combination ICI, previous cardiotoxic therapies, cardiovascular diseases)

^dDuring the first 4 doses before every ICI administration, thereafter every 3 doses

^ePatients with preexisting diarrhea

^fPatients with preexisting lung disease or radiotherapy to the lung or mediastinum

The correct Table 1 should be as indicated in the next page.